Product Highlight - Adynovate

Active ingredient: Each vial contains nominally 500 IU human coagulation factor VIII (rDNA), rurioctocog alfa pegol, corresponding to a concentration of 250 IU/mL after reconstitution with 2 mL solvent.
Indication: Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency).
Dosage & Administration: The dose and duration of the substitution therapy depend on the severity of the factor VIII deficiency, on the location and extent of the bleeding and on the patient's clinical condition.
One International Unit (IU) of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma.
Prophylaxis: For long term prophylaxis, the recommended dose is 40 to 50 IU of ADYNOVATE per kg body weight twice weekly in 3 to 4 days interval. Adjustments of doses and administration intervals may be considered based on achieved FVIII levels and individual bleeding tendency.